美国FDA宣称,根据正式发表的研究报告,使用含有屈螺酮(drospirenone)的口服避孕药可引起静脉血栓栓塞(VTE)。近期发表的两项研究报告,都是采用屈螺酮作为试验药,对照组则用左炔诺孕酮。研究结果表明,使用屈螺酮发生VTE的危险性高于对照组2～3倍。英国药品与健康产品管理局(MHRA)报告流行病学研究的结果也显示,屈螺酮发生VTE的危险性高于左炔 The U.S. FDA claims that the use of oral contraceptives containing drospirenone causes venous thromboembolism (VTE), according to a study published in the United States. Two recently published studies report the use of drospirenone as the test drug and the control group levonorgestrel. The results show that the use of drospirenone VTE risk higher than the control group 2 to 3 times. The results of the epidemiological study reported by the UK Drugs and Health Products Administration (MHRA) also showed that drospirenone is at a higher risk of VTE than levotis